| --- | --- | |---------------------|-------| | | | | | | | 1Q 2022 results | | | May 6, 2022 webcast | | | | | This presentation contains "forward-looking statements." When used in this presentation, the words "anticipate," "could," "expect," "will," "plan," "potential," "estimate," "on track," "guidance," "ongoing," "outlook," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding: the rate and timing of our cash ...

| --- | --- | |-----------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | We discover. We dare. We care. | | | Investor Relations slides \| March 2021 | | | Gal Pioneering f | | Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our R&D and clinical pipeline, our expectations regarding commercial sales of Jyseleca, the global R&D collaboration with Gilead, the amendment of our arrang ...

| --- | --- | |-------------------------------------------------------------|-------| | | | | Q3 2020 results | | | webcast | | | Onno van de Stolpe, CEO Piet Wigerinck, CSO 6 November 2020 | | | | | Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the statements regarding the global R&D collaboration with Gilead, statements relating to interactions with regulatory authorities, the timing or likeliho ...

Galápagos We discover We dare We care Investor Relations slides | August 2020 1 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the statements regarding the global R&D collaboration with Gilead, the amount and timing of potential future milestone, opt-in and/or royalty payments by Gilead, statements relating to interactions with regulatory authorities, the potential approval process for filgotinib a ...

Novel targets, better treatments Investor Presentation | June 2019 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the slides captioned "We go step by step on commercial" "Prolific late stage pipeline" "R&D ambition" "Filgotinib program" "FINCH summary up to w24" "Filgotinib: promising profile" "Inflammation market ~$65B by 2027" "$2.1B market with large unmet needs" "We are building a fibrosis port ...